Is oxytocin FDA-approved, and what does the research show?

What is oxytocin?

Oxytocin is a hormone, and the medicine is a man-made copy of it ¹, ². The Pitocin label describes it as "a nonapeptide found in pituitary extracts from mammals" ². A nonapeptide is a chain of nine amino acids, the building blocks of proteins, and the pituitary is a gland at the base of the brain. Both labels cited here say the drug is made by synthesis ¹, ².

As a medicine it is a sterile solution for injection, sold as the brand Pitocin and as unbranded Oxytocin Injection, USP ¹, ². Its approved uses are obstetric, meaning they belong to pregnancy and childbirth ¹.

Oxytocin is not a wellness, weight-loss or performance peptide. Neither label names a use for bonding, trust, mood, anxiety, sexual desire, sexual function or weight, and neither uses the phrase "love hormone" ¹, ².

Is oxytocin FDA-approved?

Yes, as a prescription injection for use around childbirth ¹, ³. Drugs@FDA, the agency's database of approved drugs, lists Oxytocin Injection under new drug application (NDA) 018248 with the marketing status "Prescription" ³. That status is as of November 9, 2026, the date of the record's data, and the record dates the application's approval to July 9, 1980 ³. The brand Pitocin, NDA 018261, is also listed as "Prescription," with an approval date of November 19, 1980 ⁶.

The indications on the Oxytocin Injection label open with a notice headed "IMPORTANT NOTICE" ¹. It says the drug "is indicated for the medical rather than the elective induction of labor" ¹. Induction is the starting of labor with medicine instead of waiting for it to begin. The label defines elective induction as "the initiation of labor for convenience in an individual with a term pregnancy who is free of medical indications" ¹. For that use, it says, the available data "are inadequate to define the benefits to risks considerations" ¹.

Before delivery, which the label calls antepartum, oxytocin is indicated "for the initiation or improvement of uterine contractions, where this is desirable and considered suitable, in order to achieve early vaginal delivery for fetal or maternal reasons" ¹. The label then lists three uses ¹. The first is "induction of labor in patients with a medical indication for the initiation of labor, such as Rh problems, maternal diabetes, pre-eclampsia at or near term, when delivery is in the best interest of mother and fetus or when membranes are prematurely ruptured and delivery is indicated" ¹. An Rh problem is a mismatch between the mother's blood group and the baby's. Pre-eclampsia is a disorder of pregnancy marked by high blood pressure, and ruptured membranes are what people call the waters breaking.

The second use is "stimulation or reinforcement of labor, as in selected cases of uterine inertia," a uterus that is contracting too weakly ¹. The third is "adjunctive therapy in the management of incomplete or inevitable abortion" ¹. Abortion is used there in its medical sense, which takes in miscarriage: elsewhere the label writes of "spontaneous or induced abortion" ¹.

After delivery, which the label calls postpartum, oxytocin is indicated "to produce uterine contractions during the third stage of labor and to control postpartum bleeding or hemorrhage" ¹. The third stage of labor is the delivery of the placenta, after the baby is born. Postpartum hemorrhage is heavy bleeding after the birth.

Drugs@FDA holds more oxytocin applications than those two. As of November 9, 2026, the date of its data, it listed nine applications with oxytocin as the active ingredient ⁷. Five had at least one product listed as "Prescription," and four had every product listed as "Discontinued" ⁷. FDA withdrew approval of three of them: NDA 19-185 in 1996 ⁸, NDA 12-285 in 1997 ⁹ and NDA 18-245, Syntocinon injection, in 2009 ¹⁰. "Discontinued," like "Prescription," is an entry in the record's marketing-status field ⁷.

One of the four is a nasal product. Syntocinon, an oxytocin nasal solution under NDA 012285, is listed as "Discontinued," its record gives no approval date, and FDA withdrew its approval effective September 8, 1997 ¹¹, ⁹. None of the nine applications listed a nasal product as "Prescription" ⁷.

An oxytocin product supplied ready-mixed in dextrose, a sugar solution, under NDA 019185, is also listed as "Discontinued" ¹². Its record carries the note "Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons" ¹². FDA withdrew its approval at the holder's request, effective April 26, 1996 ⁸, and in 2015 found the product was not withdrawn from sale for safety or effectiveness reasons ¹³.

See the FDA status of every peptide, updated weekly.

How does oxytocin work?

The labels of the approved drug describe how it works ¹, ². The Oxytocin Injection label says oxytocin "acts on the smooth muscle of the uterus to stimulate contractions" ¹. Smooth muscle is the involuntary kind found in the walls of organs. The same label says it "stimulates rhythmic contractions of the uterus, increases the frequency of existing contractions and raises the tone of the uterine musculature" ¹. Its "selective action" on that muscle shows "particularly toward the end of pregnancy, during labor and immediately following delivery" ¹.

The Pitocin label explains the timing ². Oxytocin has receptors in the myometrium, the muscle wall of the uterus, and it promotes contractions by raising the calcium inside the muscle cells ². The number of receptors "increases greatly during pregnancy, reaching a maximum in early labor at term" ². Because sensitivity depends on those receptors, the label calls the response to a given dose "very individualized" ².

The effect is brief. The Pitocin label gives a half-life in the blood, the time for half the drug to be cleared, of "about 1 to 6 minutes" ². Given into a vein, it produces a response "almost immediately" that "subsides within 1 hour" ². Injected into muscle, it acts within 3 to 5 minutes and the response lasts 2 to 3 hours ².

The Pitocin label says "oxytocin even in its pure form has inherent pressor and antidiuretic properties which may become manifest when large doses are administered," meaning it can raise blood pressure and make the body hold water ². That label says these are thought to come from its likeness to another hormone, which differs from it in only two amino acids ². The Oxytocin Injection label names that hormone and reads differently ¹. It says: "Synthetic oxytocin does not possess the cardiovascular effects, such as elevation of blood pressure, as exhibited by vasopressin found in posterior pituitary injection" ¹. The two labels differ in wording: the Pitocin label ties pressor effects to large doses, and the Oxytocin Injection label compares synthetic oxytocin with vasopressin ¹, ².

What does the research show?

Oxytocin injection is approved by FDA for the uses on its label ¹. Neither label cited here describes a clinical trial ¹, ². The Pitocin label lists five references instead, dated 1982 to 1987 ².

Studied in people, for how it is infused: a Cochrane review, a pooled analysis of trials, compared "high-dose" with "low-dose" oxytocin infusion regimens for inducing labor at term ⁴. Published on October 9, 2014, it included nine trials "involving 2391 women and their babies" ⁴. It accepted randomized trials, in which chance decides who gets which regimen, and quasi-randomized trials, in which a rule that is not truly random decides ⁴. The review says the trials "were at a moderate to high risk of bias overall" ⁴. Risk of bias is the chance that flaws in how a trial was run distorted its results.

Two delivery outcomes did not differ significantly between the regimens ⁴. One was the share of women who had not delivered vaginally within 24 hours (risk ratio 0.94, 95 percent confidence interval 0.78 to 1.14; two trials, 1,339 women) ⁴. Another was the rate of cesarean delivery (risk ratio 0.96, 0.81 to 1.14; eight trials, 2,023 women) ⁴. A risk ratio of 1 means no difference between groups, and the confidence interval is the range in which the true figure probably lies. A difference is called statistically significant when chance alone is unlikely to explain it.

Serious harm was reported by one trial for each outcome ⁴. One trial of 523 women reported serious illness or death in mothers, with no difference between regimens (risk ratio 1.24, 0.55 to 2.82) ⁴. One trial of 781 infants reported serious illness in newborns or death around birth, also with no difference (risk ratio 0.84, 0.23 to 3.12) ⁴.

Uterine hyperstimulation, meaning contractions that come too hard or too often, was more common with the "high-dose" regimens (risk ratio 1.86, 1.55 to 2.25) ⁴. That count did not specify changes in the baby's heart rate, and no trial reported hyperstimulation with such changes ⁴. The review's abstract gives no count of trials or women for this figure ⁴. The authors wrote that high-dose oxytocin "was shown to increase the rate of uterine hyperstimulation but the effects of this are not clear" ⁴.

Time from induction to delivery did not differ in the pooled analysis (mean difference -0.90 hours, -2.28 to +0.49; five studies) ⁴. A mean difference is the gap between the two groups' averages. The review's abstract adds: "Removal of high bias studies reveals a significant reduction of induction to delivery interval" (mean difference -1.94 hours, -0.99 to -2.89; 489 women) ⁴. The review's abstract gives no count of women for the first of these two figures and no count of trials for the second ⁴. The review's plain language summary says "the induction to delivery interval was significantly shorter with high-dose oxytocin compared to low-dose oxytocin" ⁴.

The authors concluded that their findings "do not provide evidence that high-dose oxytocin increases either vaginal delivery within 24 hours or the caesarean section rate" ⁴. They added that the conclusions "are specific to the definitions used in this review" ⁴.

Studied in people, for autism, which is not an approved use: a phase 2 trial tested oxytocin given into the nose (intranasally), not as the approved injection ⁵. It was published on October 14, 2021 ⁵. Phase 2 is the middle stage of drug testing. The trial was placebo-controlled, comparing oxytocin with a dummy (placebo) given the same way over 24 weeks, in children and adolescents aged 3 to 17 with autism spectrum disorder ⁵. Of the 290 enrolled, 146 were randomly assigned to oxytocin and 144 to placebo ⁵.

The main measure was a 13-item social-withdrawal score on which a higher score means less social interaction ⁵. The analysis took in 139 participants in the oxytocin group and 138 in the placebo group ⁵. The average change, adjusted by the trial's statistical model, was -3.7 with oxytocin and -3.5 with placebo ⁵. The difference of -0.2 was not statistically significant (95 percent confidence interval -1.5 to 1.0; P = 0.61) ⁵. The P value measures how easily chance alone could produce such a gap, and 0.61 is far above the usual bar of 0.05.

Secondary outcomes "generally did not differ between the trial groups," and the incidence and severity of adverse events were similar in the two groups ⁵. The National Institute of Child Health and Human Development funded the trial ⁵. None of the sources cited here studies oxytocin for weight loss, mood, anxiety, libido or bonding.

What are the side effects?

The Pitocin label carries a boxed warning, headed "IMPORTANT NOTICE" ². It reads: "Elective induction of labor is defined as the initiation of labor in a pregnant individual who has no medical indications for induction. Since the available data are inadequate to evaluate the benefits-to-risks considerations, Pitocin is not indicated for elective induction of labor" ². The Oxytocin Injection label prints its own "IMPORTANT NOTICE," worded differently, in a ruled table within its indications ¹.

That label's warning concerns the route and the setting ¹. When given to induce or stimulate labor, oxytocin "must be administered only by the intravenous route and with adequate medical supervision in a hospital" ¹. Patients receiving it intravenously "must be under continuous observation by trained personnel" ¹. The label states: "Overstimulation of the uterus by improper administration can be hazardous to both mother and fetus" ¹.

The Oxytocin Injection label reports deaths of mothers and of fetuses with drugs of this kind used in labor ¹. Its words are: "Maternal deaths due to hypertensive episodes, subarachnoid hemorrhage, rupture of the uterus and fetal deaths due to various causes have been reported associated with the use of parenteral oxytocic drugs for induction of labor and for augmentation in the first and second stages of labor" ¹. Hypertensive episodes are bouts of high blood pressure. Parenteral means given by injection or infusion, an oxytocic is a drug that makes the uterus contract, and a subarachnoid hemorrhage is bleeding around the brain.

The adverse reactions the Oxytocin Injection label lists in the mother are anaphylactic reaction, postpartum hemorrhage, cardiac arrhythmia, "fatal afibrinogenemia," nausea, vomiting, premature ventricular contractions and pelvic hematoma ¹. An anaphylactic reaction is a severe allergic reaction, and afibrinogenemia is a lack of a protein the blood needs to clot. A cardiac arrhythmia is an irregular heartbeat, premature ventricular contractions are extra beats from the heart's lower chambers, and a pelvic hematoma is a pool of blood in the pelvis.

The label adds: "Excessive dosage or hypersensitivity to the drug may result in uterine hypertonicity, spasm, tetanic contraction or rupture of the uterus" ¹. Hypersensitivity is an allergy-like over-reaction to a drug. The label describes hyperstimulation as "strong (hypertonic) or prolonged (tetanic) contractions" ¹.

Infusion carries a risk of its own. The Oxytocin Injection label says oxytocin has "an intrinsic antidiuretic effect," which makes the body hold on to water ¹. Water intoxication is a dangerous dilution of the blood's salts by too much retained water. The label says: "Severe water intoxication with convulsions and coma has occurred," and it associates this with a slow infusion given over a long period ¹. It adds: "Maternal death due to oxytocin-induced water intoxication has been reported" ¹.

For the fetus or infant, the Oxytocin Injection label lists reactions by cause ¹. Those it ties to the contractions the drug induces are bradycardia, a slow heartbeat; "premature ventricular contractions and other arrhythmias"; "permanent CNS or brain damage"; and "fetal death" ¹. CNS stands for central nervous system, the brain and spinal cord.

Those it ties to the use of oxytocin in the mother are "neonatal retinal hemorrhage," "low Apgar scores at five minutes" and "neonatal jaundice" ¹. Neonatal means in a newborn, a retinal hemorrhage is bleeding at the back of the eye, and jaundice is a yellowing of the skin and eyes. An Apgar score is a quick check of a newborn's condition. The Pitocin label adds: "Neonatal seizures have been reported with the use of Pitocin" ².

The Oxytocin Injection label contraindicates the drug in eight conditions, meaning it says the drug should not be used in them ¹. They include "significant cephalopelvic disproportion," where the baby's head does not fit the mother's pelvis, and "unfavorable fetal positions or presentations which are undeliverable without conversion prior to delivery, i.e., transverse lies" ¹. They include "obstetrical emergencies where the benefit-to-risk ratio for either the fetus or the mother favors surgical intervention" and "cases of fetal distress where delivery is not imminent" ¹. The others are "prolonged use in uterine inertia or severe toxemia," "hypertonic uterine patterns," "patients with hypersensitivity to the drug," and "induction or augmentation of labor in those cases where vaginal delivery is contraindicated, such as cord presentation or prolapse, total placenta previa, and vasa previa" ¹.

A transverse lie is a baby lying sideways in the uterus, and toxemia is an older name for pre-eclampsia. Fetal distress means signs, often in the heart rate, that the baby is short of oxygen. In cord presentation or prolapse, the umbilical cord lies or slips ahead of the baby. In placenta previa and vasa previa, the placenta or the baby's blood vessels lie across the cervix, the neck of the uterus.

The label also names conditions in which, "except in unusual circumstances," oxytocin should not be given ¹. They are "prematurity, borderline cephalopelvic disproportion, previous major surgery on the cervix or uterus including Caesarean section, overdistention of the uterus, grand multiparity or invasive cervical carcinoma" ¹. Overdistention is a uterus stretched beyond its usual size, and grand multiparity means having given birth many times.

On birth defects, the label says: "Based on the wide experience with this drug and its chemical structure and pharmacological properties, it would not be expected to present a risk of fetal abnormalities when used as indicated" ¹. On drug interactions, it says: "Severe hypertension has been reported when oxytocin was given three to four hours following prophylactic administration of a vasoconstrictor in conjunction with caudal block anesthesia" ¹. Prophylactic means given to prevent a problem, a vasoconstrictor is a drug that narrows blood vessels, and a caudal block is an anesthetic injected at the base of the spine. On breastfeeding, it says: "It is not known whether this drug is excreted in human milk" ¹.

In sport

Oxytocin is not named on the 2026 Prohibited List of WADA, the World Anti-Doping Agency, in its section S2 on peptide hormones or anywhere else ¹⁴. Because the drug is given by intravenous infusion, the list's method rule M2.2 bears on the route ¹⁴. It prohibits "Intravenous infusions and/or injections of more than a total of 100 mL per 12-hour period except for those legitimately received in the course of hospital treatments, surgical procedures or clinical diagnostic investigations" ¹⁴.

What JumpstartMD offers

JumpstartMD does not prescribe oxytocin. Our peptide library covers it so you have the facts on its FDA status and the evidence, current as of November 10, 2026.

Ready to talk?

Book FREE Consultation

Share your details and a JumpstartMD team member will reach out shortly. Or call 408.478.3496 for your free, no-obligation consultation.

Share your details and a JumpstartMD team member will reach out when we open.

Disclaimer

Compounded medications are not FDA-approved, and FDA does not review their safety, effectiveness, or quality before they are marketed. A licensed clinician decides after an evaluation whether a peptide is appropriate for you, and not every patient will qualify.